Stem cell supporters await their Obama moment

By Maggie Fox, Health and Science Editor

WASHINGTON (Reuters) - Stem cell advocates and researchers are eagerly awaiting the moment next year when president-elect Barack Obama rescinds a directive that limits federal funding of human embryonic stem-cell research.

The directive was one of President George W. Bush’s first major acts after taking office in 2001, and Obama plans to reverse it quickly, according to the co-chair of his transition team, John Podesta.

The result should be a surge of funding and interest, said David Greenwood of Geron Corp., whose shares were up more than 10 percent on Monday along with those of other companies with a heavy interest in the field.

“We have been waiting for the day,” Greenwood said in a telephone interview.

“Hallelujah — at last!” agreed Dr. Robert Lanza of Massachusetts-based Advanced Cell Technology, which has been struggling to find funding.

While private companies have been doing as much as they can, the weight of the government’s National Institutes of Health is vital to get the process going, the experts agreed.

“We at this company have spent probably $170 million on embryonic stem cells,” Greenwood said.

“I think our $170 million probably is equal to what all other stem cell companies have managed to raise, and that’s not a large sum to do industrial science, compared to the $30 billion a year the NIH has.”

Advocates say stem cell-related research could lead to a whole new field of regenerative medicine, in which patients could get transplants and treatments for Parkinson’s, juvenile diabetes, cancer, injuries and a range of other ills.

Bush has been at odds with Congress, researchers and advocates for years over the issue. Stem cells are the body’s master cells. Most sources, from blood and tissue, are not controversial.

But days-old embryos called blastocysts are made up of so-called pluripotent stem cells, which can give rise to all the other cells and tissues in the body. Human embryonic stem cells were only discovered in 1998.

The 1995 Dickey Amendment, passed by Congress every year since, forbids the use of federal funds for the destruction or endangerment of embryos for research.

EXTENDED RESTRICTION

In 2001, Bush extended this restriction via executive order to research that uses stem cells from human embryos — with the small exception of a few batches, called lines, of stem cells that had already been created.

Congress has tried to overrule the decision with broad stem cell legislation, but Bush has vetoed every effort.  Continued…

Source

--------------------------------------------------------------------------------------------
Related Posts:


By Esha Dey BANGALORE (Reuters) - Shares of companies developing therapies based on stem cells surged on Monday, after confirmation over the weekend that U.S. president-elect Barack Obama plans to reverse an existing executive order against federal funding of embryonic stem-cell research. Companies such as Geron Corp and StemCells Inc saw a sharp rise in their stock

Full Post: Stem-cell firms surge as Obama fuels funding hopes
--------------------------------------------------------------------------------------------

LONDON (Reuters) - European regulators on Thursday ruled against allowing a patent on developing human embryonic stem cells, a decision that could stifle research by stem cell companies for commercial purposes. An appeal panel at the European Patent Office upheld a June decision to reject a patent application regarding the use of stem cells filed by

Full Post: European agency rules against stem cell patents
--------------------------------------------------------------------------------------------

WASHINGTON (Reuters) - The U.S. Food and Drug Administration has cleared the way for the world’s first study of human embryonic stem cell therapy, Geron Corp said on Friday. The California biotechnology company plans to start a clinical trial to try to use the stem cells to regrow nerve tissue in patients with acute spinal cord

Full Post: FDA allows first test of human stem cell therapy
--------------------------------------------------------------------------------------------

By Ben Hirschler LONDON (Reuters) - Danish drugmaker Novo Nordisk A/S is turning to stem cells in the hunt for a cure for diabetes. The world leader in diabetes care said on Thursday it had launched a new collaboration to develop a treatment for type 1 diabetes by programing stem cells to turn into insulin-producing cells. The alliance

Full Post: Novo taps stem cells in hunt for diabetes cure
--------------------------------------------------------------------------------------------

By Maggie Fox, Health and Science Editor WASHINGTON (Reuters) - Rogue clinics around the world may be exploiting hope and ignorance by offering unproven stem cell therapies, a group of stem cell experts said in a report released on Wednesday. The International Society for Stem Cell Research released guidelines for researchers and regulators, and a guidebook for

Full Post: “Rogue” stem cell clinics exploit hope: report

Site Navigation

Most Read

Search